US Bancorp DE lessened its holdings in GlaxoSmithKline plc (NYSE:GSK) by 38.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 210,492 shares of the pharmaceutical company’s stock after selling 130,080 shares during the period. US Bancorp DE’s holdings in GlaxoSmithKline were worth $7,467,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in GSK. Gotham Asset Management LLC lifted its stake in shares of GlaxoSmithKline by 4.3% in the 2nd quarter. Gotham Asset Management LLC now owns 26,495 shares of the pharmaceutical company’s stock valued at $1,142,000 after purchasing an additional 1,103 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of GlaxoSmithKline by 18.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,960 shares of the pharmaceutical company’s stock valued at $818,000 after purchasing an additional 2,968 shares during the last quarter. Americafirst Capital Management LLC acquired a new stake in shares of GlaxoSmithKline in the 2nd quarter valued at $299,000. Nomura Holdings Inc. acquired a new stake in shares of GlaxoSmithKline in the 2nd quarter valued at $265,000. Finally, Verition Fund Management LLC acquired a new stake in shares of GlaxoSmithKline in the 2nd quarter valued at $1,300,000. 9.52% of the stock is owned by institutional investors and hedge funds.
GlaxoSmithKline plc (GSK) traded up $0.39 during trading hours on Friday, hitting $37.70. 4,625,296 shares of the stock traded hands, compared to its average volume of 5,090,000. GlaxoSmithKline plc has a one year low of $34.52 and a one year high of $44.53. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.39 and a current ratio of 0.60. The company has a market cap of $91,790.00, a P/E ratio of 43.33, a price-to-earnings-growth ratio of 2.34 and a beta of 0.98.
GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The company had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. research analysts forecast that GlaxoSmithKline plc will post 2.85 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be issued a dividend of $0.633 per share. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. The ex-dividend date is Thursday, February 22nd. This represents a $2.53 annualized dividend and a dividend yield of 6.72%. GlaxoSmithKline’s payout ratio is presently 234.48%.
GSK has been the subject of several analyst reports. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $35.04 to $35.85 in a research note on Monday, November 27th. Zacks Investment Research lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Thursday, January 4th. ValuEngine lowered shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research report on Thursday, January 11th. Finally, Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 16th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and an average price target of $38.97.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/17/us-bancorp-de-sells-130080-shares-of-glaxosmithkline-plc-gsk.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.